Somewhat Positive Media Coverage Somewhat Unlikely to Impact Sage Therapeutics (NASDAQ:SAGE) Stock Price

News headlines about Sage Therapeutics (NASDAQ:SAGE) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sage Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.7299440751583 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern’s scoring:

• SAGE Therapeutics Inc (SAGE) Price Moves Above the Cloud – Evergreen Caller (evergreencaller.com)
• Are There Any Catalysts to Propel Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) or Esterline Technologies … – FLBC News (flbcnews.com)
• BMO Capital Markets Reiterates Buy Rating for Sage Therapeutics, Inc. (NASDAQ:SAGE) (americanbankingnews.com)
• Cognitive Impairment Associated with Schizophrenia (CIAS) – Pipeline Review with Therapeutic Drugs Profile – H2 2017 (sbwire.com)
• Sage Therapeutics, Inc. (SAGE) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)

Sage Therapeutics (NASDAQ:SAGE) traded down 2.53% during mid-day trading on Monday, hitting $79.75. 320,617 shares of the stock traded hands. Sage Therapeutics has a 12-month low of $35.02 and a 12-month high of $88.93. The firm’s 50-day moving average is $80.92 and its 200-day moving average is $68.56. The company’s market cap is $2.98 billion.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.09. Equities research analysts expect that Sage Therapeutics will post ($6.76) EPS for the current year.

A number of analysts have recently commented on SAGE shares. ValuEngine raised shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cowen and Company started coverage on shares of Sage Therapeutics in a research note on Monday, June 12th. They set an “outperform” rating and a $95.00 target price for the company. Canaccord Genuity set a $110.00 target price on shares of Sage Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, April 12th. BMO Capital Markets reissued a “buy” rating and set a $82.00 target price on shares of Sage Therapeutics in a research note on Friday. Finally, Stifel Nicolaus reissued a “buy” rating and set a $90.00 target price on shares of Sage Therapeutics in a research note on Friday, July 14th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $85.82.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by [[site]] and is owned by of [[site]]. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at [[permalink]].

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.